Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets
British Journal of Pharmacology · 2026-08-12
DOI: 10.1111/bph.70634 ↗At a glance
Übersichtsarbeit in British Journal of Pharmacology, published online on 2026-08-12. Written by Charlie Leboff and 3 co-authors. Institution: Department of Biosciences, Centre for Systems Health and Integrated Metabolic Research, John van Geest Cancer Research Centre, School of Science and …. 211 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory, oncogenic and proangiogenic pathways. Inflammation, cancer and angiogenesis are interlinked through a network of signals and pathways that reinforces itself through feedback loops. Inflammation triggers vessel formation to transfer immune cells and nutrients, and consequently the new vessels enhance the supply of inflammatory cells and factors. Chronic inflammation induces oncogenic transformation and angiogenesis, induced by tumour‐derived signals, support tumour growth and provide the route for distal metastasis. Here we review the implication of lncRNAs in these processes and interactions in the gastrointestinal tract, with a special focus on inflammation and cancer angiogenesis. LncRNAs, due to their highly cell‐, tissue‐ and disease‐specific expression, are attractive targets for the development of novel therapeutics with limited off‐target effects and toxicity. We discuss new discoveries which highlight the value of lncRNA targeting as therapeutic applications, in gastrointestinal inflammation and cancer angiogenesis, and identify gaps in our current knowledge and understanding. We illustrate advancing approaches, their advantages and challenges for the pharmacological targeting of lncRNAs.
Subjects
Author keywords
Authors and institutions
- Department of Biosciences, Centre for Systems Health and Integrated Metabolic Research, John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, UK.
ORCID profiles: Charlie Leboff, Pamela Calle-Mendoza, Maria Hatziapostolou, Christos Polytarchou
Cite
APA
Leboff, C., Calle-Mendoza, P., Hatziapostolou, M., & Polytarchou, C. (2026). Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets. British Journal of Pharmacology. https://doi.org/10.1111/bph.70634
Vancouver
Leboff C, Calle-Mendoza P, Hatziapostolou M, Polytarchou C. Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets. British Journal of Pharmacology. 2026. doi:10.1111/bph.70634
BibTeX
@article{Leboff2026,
author = {Leboff, Charlie and Calle-Mendoza, Pamela and Hatziapostolou, Maria and Polytarchou, Christos},
title = {Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets},
journal = {British Journal of Pharmacology},
year = {2026},
doi = {10.1111/bph.70634}
}
EUVIMED